The bifurcated nature of current litigation (with gastrointestinal claims proceeding federally and vision loss claims advancing through state courts) creates pressure on manufacturers from multiple directions simultaneously, increasing the likelihood that Novo Nordisk and Eli Lilly will eventually pursue comprehensive settlement frameworks addressing both injury types
Phase 2 data does not capture long-term safety
Compression garment: required for several weeks
In the ATTAIN-1 trial, adverse events led to treatment discontinuation in up to 10.3 percent of patients on the drug, compared to only 2.7 percent on placebo
25 patients with long COVID (19 females, 6 males, mean age 44.3, range 2767)
Patients were randomly assigned in a 1:1 ratio to receive once-daily oral semaglutide (n = 4825) with a maximal dose of 14 mg or placebo (n = 4825), as well as standard care